New NMO Clinical Trial

Now enrolling at the Mayo Clinic

Mayo Clinics in Minnesota and Arizona have launched a new clinical trial for NMO patients. The purpose of the database is to determine if eculizumab, a monoclonal antibody that interferes with complement activation, reduces the frequency of NMO attacks or improves outcome.

The Primary Outcome Measures the reduction in number of NMO attacks and determines safety for NMO.The Secondary Outcome Measures improvement in the quality of life, visual function and walking, and determines drug levels in blood and CSF.

Experimental Drug Intervention:

The patient will receive eculizumab at a dose of 600mg intravenously (by infusion into the vein) each week for

4 weeks, 900mg intravenously at the fifth week, and 900mg every 2 weeks for 48 weeks.

The first infusion will be given at Mayo Clinic (Minnesota or Arizona); subsequent infusions will be

administered at home by a nurse employed by Coram Home infusion services (coordinated by a Study

physician).

Eligibility

Patients must be NMO-IgG seropositive, and have a diagnosis of NMO (defined by 2006 criteria) or an NMO

spectrum disorder (recurrent optic neuritis or longitudinally extensive transverse myelitis).

Clinical evidence must document at least 2 relapses in the past 6 months or 3 relapses in the past 12

months (at least 1 relapse in the preceding 6 months).

The patient must be at least 18 years old.

If you are interested in this study and would like to learn more about it, please contact the investigators at the following locations:

Mayo Clinic - Arizona Principal Investigator: Dean M. Wingerchuk, M.D.

Contact: Irene Galasky 480-342-6104

galasky.irene@mayo.edu

Mayo Clinic - Minnesota Principal Investigator: Sean J. Pittock, M.D.

Contact: Karen Brekke 507-538-3761

brekke.karen@mayo.edu

Contact: Connie Brekke 507-266-3196

brekke.connie@mayo.edu

For more information please visit http://clinicaltrials.gov/ct2/show/NCT00904826